60 likes | 226 Views
Population Health. Research Institute. Steroids In caRdiac Surgery (SIRS) Trial. Population Health Research Institute Hamilton Health Sciences/McMaster University Hamilton, Canada. SIRS was funded by grants from the Canadian Institutes of Health Research (CIHR)
E N D
Population Health Research Institute Steroids In caRdiac Surgery (SIRS) Trial Population Health Research Institute Hamilton Health Sciences/McMaster University Hamilton, Canada SIRS was funded by grants from the Canadian Institutes of Health Research (CIHR) and the Canadian Network and Centre for Trials Internationally(CANNeCTIN)
Trial Flow Diagram Randomized (n = 7,507) Allocated to steroid* (n = 3,755) Allocated to Placebo (n = 3,752) Lost to follow-up (n = 1) Did not receive study drug (n = 105) Lost to follow-up (n = 0) Did not receive study drug (n = 106) Analyzed by intention-to-treat (n = 3,752) Complete follow-up data (n = 3,751) Analyzed by intention-to-treat (n = 3,755) Complete follow-up data (n = 3,754) *500 mg IV Methylprednisolone given intra-operatively
Conclusion Methylprednisolone does not reduce death or major morbidity at 30 days for high-risk patients undergoing cardiac surgery with the use of cardiopulmonary bypass. Methylprednisolone increases the risk of early post-operative myocardial infarction, defined by CK-MB biomarker release.
Implications Methylprednisolone should not be administered prophylactically to high-risk patients undergoing cardiac surgery with the use of cardiopulmonary bypass. Further work is necessary to understand the mechanism of steroid-driven myocardial infarction.